Evaxion Biotech A/S (EVAX)

NASDAQ: EVAX · IEX Real-Time Price · USD
1.99
+0.10 (5.29%)
At close: Jun 29, 2022 3:46 PM
2.03
+0.04 (2.01%)
After-hours: Jun 29, 2022 4:24 PM EDT
5.29%
Market Cap 46.28M
Revenue (ttm) n/a
Net Income (ttm) -26.23M
Shares Out 23.26M
EPS (ttm) -1.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,637
Open 1.89
Previous Close 1.89
Day's Range 1.81 - 1.99
52-Week Range 1.51 - 25.04
Beta n/a
Analysts Buy
Price Target 16.07 (+707.5%)
Earnings Date Aug 11, 2022

About EVAX

Evaxion Biotech A/S, an artificial intelligence (AI)-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. The company develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase 1/2a trial for indications, such as metastatic and unresectable melanoma; EVX-02, a... [Read more...]

Industry Biotechnology
IPO Date Feb 5, 2021
Employees 61
Stock Exchange NASDAQ
Ticker Symbol EVAX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for EVAX stock is "Buy." The 12-month stock price forecast is 16.07, which is an increase of 707.54% from the latest price.

Price Target
$16.07
(707.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Evaxion Biotech To Test EVX-03 DNA Vaccine For Non-Small Cell Lung Cancer

Evaxion Biotech A/S (NASDAQ: EVAX) has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022. We currently have...

Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer

COPENHAGEN, Denmark, June 23, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-drive...

Bears are Losing Control Over Evaxion Biotech AS Sponsored ADR (EVAX), Here's Why It's a 'Buy' Now

Evaxion Biotech AS Sponsored ADR (EVAX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong...

Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital

COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-power...

Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update

COPENHAGEN, Denmark, May 11, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven...

Good Penny Stocks To Buy Now? 4 For Your May Watch List

Penny stocks to watch this week. The post Good Penny Stocks To Buy Now?

Other symbols: CLOVMULN

Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial f...

COPENHAGEN, Denmark, May 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve t...

Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11

COPENHAGEN, Denmark, April 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driv...

Evaxion to Utilize Personalis' ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Mel...

MENLO PARK, Calif. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis' ImmunoID NeXT Platform in...

Other symbols: PSNL

Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

COPENHAGEN, Denmark, March 22, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driv...

Evaxion Biotech Strengthens Management Team with Two Senior Appointments

COPENHAGEN, Denmark, March 14, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) is a clinical-stage biotechnological company specializing in the development of AI-powered immunotherapies to i...

Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02

COPENHAGEN, Denmark, March 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has now f...

Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck

COPENHAGEN, Denmark, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve ...

Evaxion Biotech AS Sponsored ADR (EVAX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Evaxion Biotech AS Sponsored ADR (EVAX), indicating that the stock has found support. This, combined with an upward trend in ea...

Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for T...

COPENHAGEN, Denmark, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve ...

Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwri...

COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-drive...

Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update

COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-drive...

Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering

COPENHAGEN, Denmark, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-drive...

EVAX Stock: 10 Things to Know as Little-Known Evaxion Rockets 100% Today

With its stock price up nearly 200% in today's premarket, it's time for investors to get to known Danish company Evaxion Biotech. The post EVAX Stock: 10 Things to Know as Little-Known Evaxion Rockets 1...

Evaxion Biotech Announces Filing of Registration Statement in the U.S for Proposed Follow-on Public Offering to Raise...

COPENHAGEN, Denmark, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-drive...

Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in...

COPENHAGEN, Denmark, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve ...

Evaxion Biotech Wins Frost & Sullivan 2021 Enabling Technology Leadership Award

COPENHAGEN, Denmark, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-drive...

Evaxion Biotech to Present Work on AI-Immunology Core Technology at Immuno UK 2021

COPENHAGEN, Denmark, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-drive...

Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer

COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driv...

Evaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update

COPENHAGEN, Denmark, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-drive...